Sanofi | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
Sanofi | 6-K: New Phase 2b Results for Amlitelimab Support Potential for Best-in-Class Maintenance of Response in Atopic Dermatitis
Sanofi | S-8 POS: S-8 POS
Sanofi | 6-K: Colletion of Recent Announcements
Sanofi | 6-K: Peer Support, Flexible Work Arrangements, Salary for a Year: Sanofi Launches Global Program for Employees Affected by Cancer and Critical Illnesses
Sanofi | 6-K: Dupixent® FDA Approved as First and Only Treatment Indicated for Children Aged 1 Year and Older with Eosinophilic Esophagitis (EoE) and François-Xavier Roger Appointed Chief Financial Officer, Member of Sanofi Executive Committee
Sanofi | 6-K: Sanofi to Acquire Inhibrx, Inc., Adding Potential Best-in-Class Rare Disease Asset for Alpha-1 Antitrypsin Deficiency to Pipeline
Sanofi | 6-K: Brian Foard Appointed Head of Specialty Care Global Business Unit, Member of Sanofi Executive Committee
Sanofi | 6-K: Sanofi Announces End of Program Evaluating Tusamitamab Ravtansine After a 2L NSCLC Phase 3 Trial Did Not Meet a Primary Endpoint
Sanofi | 6-K: Colletion of Recent Announcements
Sanofi | 6-K: Dupixent® Significantly Reduced COPD Exacerbations in Second Positive Phase 3 Trial, Accelerating FDA Submission and Confirming Potential to Become First Approved Biologic for This Serious Disease
Sanofi | 6-K: Specialty Care Growth, Strong Launch Uptake of Beyfortus® and ALTUVIIIO® Drive Solid Q3 Results
Sanofi | 6-K: Sanofi Enters Next Chapter of Play to Win Strategy
Sanofi | 6-K: Colletion of Recent Announcements
Sanofi | 6-K: Colletion of Recent Announcements
Sanofi | 6-K: Sanofi Announces Agreement for Potential First-in-Class Vaccine Against Extraintestinal Pathogenic E. Coli and Sanofi and Teva Announce Exclusive Collaboration to Deliver Inflammatory Bowel Disease Treatment
Sanofi | 6-K: Colletion of Recent Announcements
Sanofi | 6-K: Sanofi announces changes to its Executive Committee
Sanofi | 6-K: U.S. CDC Advisory Committee unanimously recommends routine use of Beyfortus™ (nirsevimab-alip) to protect infants against RSV disease
Sanofi | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
No Data